Type of Assessment:
A High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreIncreased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreThe role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy
Lung Cancer 2026 July [Link] Farhad Kosari, Paul Baas, Maria Disselhorst, Kim Lauer, Tobias Peikert, Stephen Murphy, Janet Schaefer Klein, Aaron S Mansfield Abstract Assessing the contributions of microRNAs to gene expression regulation and treatment outcomes in malignancies is challenging. Traditional analyses focus on individual microRNAs, overlooking competitive binding among RNA species sharing common microRNAs.…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreMetabolic vulnerabilities in pleural mesothelioma
Oncogenesis 2026 May 20 [Link] Sílvia Plans-Marin, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Mesothelioma is a rare tumour of mesothelial origin that is often diagnosed at advanced stages. Despite recent approval of immunotherapy, the prognosis of mesothelioma remains dismal. Growing evidence links tumour metabolism to the molecular mechanisms driving mesothelioma’s aggressiveness, therapeutic resistance and poor outcomes.…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreA case of diffuse malignant peritoneal mesothelioma: case report and literature review
Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…
Read MoreQuantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort
Academic Radiology 2026 May 15 [Link] Ritu R Gill, William G Richards, Emanuele Mazzola, Beow Y Yeap, Raphael Bueno Abstract Rationale and objectives: Accurate clinical staging in pleural mesothelioma (PM) is limited by the subjectivity of conventional imaging assessment, which introduces inter- and intraobserver variability. Tumor volume, pleural thickness and diaphragmatic thickness measurements individually prognostic…
Read MoreRethinking continuity in general practice for people with incurable illness: a qualitative case study of mesothelioma
The British Journal of General Practice 2026 May 14 [Link] Emilie Couchman, Steph Ejegi-Memeh, Sarah Mitchell, Clare Gardiner Abstract Background: Continuity in general practice has clear benefits but is difficult to achieve. Existing research has identified groups of individuals who may especially benefit from continuity, such as those with a terminal condition. Mesothelioma is an…
Read MoreClinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings
Journal of Clinical Pathology 2026 June 18 [Link] Dina Moustafa Thabit, Dalia M Thabet Abstract Aims: Distinguishing epithelioid malignant mesothelioma (EMM) from poorly differentiated lung adenocarcinoma (PD-LUAD) remains challenging, particularly when 21.7% of PD-LUADs lack lineage-specific markers (thyroid transcription factor-1 (TTF-1)/Napsin A), creating a diagnostic blind spot. While GATA-binding protein 3 (GATA3) is established in…
Read More
Skip to content